It demonstrated significant pre-clinical in vitro and in vivo efficacy in AML cells with FLT3-ITD [17,20] and TKD mutations [21], RUNX1/ETO translocation [22] and MLL rearrangement [15,23]. This evidence concerns the gene KMT2A and acute myeloid leukemia.